CARNITOR (levocarnitine) by Leadiant Biosciences is clinical pharmacology carnitor (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. First approved in 1985.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
CARNITOR (levocarnitine) is a naturally occurring substance essential for mammalian energy metabolism that facilitates long-chain fatty acid entry into cellular mitochondria. It is indicated for primary and secondary carnitine deficiency, including inborn errors of metabolism such as glutaric aciduria II, methylmalonic aciduria, propionic acidemia, and medium-chain fatty acyl-CoA dehydrogenase deficiency. The drug works by promoting excretion of excess organic or fatty acids and clearing toxic acylCoA compounds through formation of acylcarnitine.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a transitional portfolio role requiring defensive and lifecycle management strategy.
CLINICAL PHARMACOLOGY CARNITOR (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids…
Worked on CARNITOR at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Carnitine Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CARNITOR offers limited career growth potential given the approaching loss of exclusivity and minimal clinical pipeline activity; opportunities are concentrated in defensive commercial strategy, rare disease patient engagement, and market access roles. The product is suitable for professionals interested in orphan/rare disease expertise, reimbursement complexity, and niche market dynamics rather than high-growth franchise development.